Navigation Links
Drug shown to reverse radioiodine resistance in some advanced thyroid cancers
Date:2/13/2013

NEW YORK, FEBRUARY 13, 2013 The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center.

Published in the February 14 issue of the New England Journal of Medicine, the study offers new hope for patients with a disease that can have a poor prognosis. An estimated 56,000 new cases of thyroid cancer are diagnosed each year in the United States, and that number is on the rise, according to the National Cancer Institute. About 5 percent of these patients will eventually develop distant metastatic disease, and the ten-year survival rate for patients with metastatic tumors that fail to respond to RAI is approximately 10 percent.

According to James A. Fagin, MD, Memorial Sloan-Kettering's Endocrinology Service Chief and senior author on the study, many trials have tested strategies for overcoming RAI resistance in metastatic thyroid cancers, but none have been successful. Previous studies have shown that a cell's ability to absorb RAI is controlled by the MAPK pathway, so Dr. Fagin and his colleagues examined whether selumetinib, an MAPK inhibitor, could reverse RAI resistance by inhibiting the signaling of genetic mutations in this pathway. The approach proved effective, especially in patients with thyroid cancers that contain a mutation in the RAS gene a component of the MAPK pathway.

"Blocking this key pathway increased the uptake of iodine, making radioiodine treatment potentially effective once again," said Fagin, who led this research in cells and in mice.

Following a five-day low-iodine diet, researchers administered selumetinib to 20 patients with tumors resistant to radioiodine. After four weeks, patients underwent a diagnostic scan that measured how much RAI their tumors would absorb. In eight patients, including all five with an
'/>"/>

Contact: Caitlin Hool
HOOLC@MSKCC.ORG
212-639-3573
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Community-based nutrition education shown to be successful in increasing calcium intake
2. Compounds shown to thwart stubborn pathogens social propensity
3. Antioxidant shown to reduce blindness risk in extremely premature babies
4. Vitamin D with calcium shown to reduce mortality in elderly
5. Gallbladder shown as potential stem cell source for regenerative liver and metabolic disease
6. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
7. Promising compound restores memory loss and reverses symptoms of Alzheimers
8. Scripps Florida scientists design molecule that reverses some fragile X syndrome defects
9. BUSM researchers find potential key to halt progression, reverse damage from emphysema
10. Medusa reimagined: Caltech-led team reverse engineers a jellyfish with the ability to swim
11. Drug could reverse scourge of cerebral malaria for survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... examining how the hormone jasmonate works to protect plants ... repressor of the jasmonate signaling pathway makes its way ... hope the recently published discovery will eventually help farmers ... harmful chemicals., "This is a small piece of a ...
... observations have revealed the first direct evidence of smoke ... tarnishing the ice with soot and making it more ... American Geophysical Union meeting this week, an Ohio State ... Infrared Pathfinder Satellite Observation (CALIPSO) satellite, which captured smoke ...
... 5, 2012Researchers at St. Michael,s hospital have identified 29 ... spread of kidney cancer. The discovery will help physicians ... and provide those patients with more intensive treatment and ... the most treatment-resistant malignancies and patients have dismal prognosis," ...
Cached Biology News:Biologists unlocking the secrets of plant defenses, 1 piece at a time 2Fire and ice: Wildfires darkening Greenland snowpack, increasing melting 2
(Date:5/6/2015)... May 06, 2015 Histogen, Inc., ... the products of cells grown under simulated embryonic ... immunomodulatory treatment candidate for melanoma during the 2015 ... place May 6-9, 2015 in Atlanta, GA. , ... produce a soluble material with anti-oncologic properties, with ...
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines (NASDAQ: ... its initial public offering of 9,367,708 shares of ... $18.00 per share, including shares of common stock ... of their option to purchase additional shares. The ... Blueprint Medicines were approximately $168.6 million, before underwriting discounts ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 VetStem ... Science Animal Health, Jeffrey Schaffer, DVM, as Director ... over 15 years of experience in the veterinary ... great addition to our veterinarian lead organization”. ... explains. “Dr. Schaffer will be responsible for all ...
(Date:5/5/2015)... Israel , May 5, 2015  Tikcro ... Company was approved to continue trading on OTCQB  ... OTCQB Marketplace allows for a continuous ... broker-dealers. Investors can have real-time quotes and market ... The OTCQB Marketplace includes U.S. and ...
Breaking Biology Technology:Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2Blueprint Medicines Announces Closing of Initial Public Offering 2Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2
... Cardica, Inc.,(Nasdaq: CRDC ) and Cook Medical ... the development of vascular closure,devices. Cook Medical will pay ... product for the closure device product line. "We ... to the next device in our vascular closure product ...
... Spectral Diagnostics Inc.,(TSX:SDI) today announced the market launch ... product for sepsis, in Germany through,A. Menarini Diagnostics ... Sepsis is the third most common cause of ... treatment of severe sepsis consumes,about one third of ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer, is scheduled to present at the 2007 ... at 8:00 a.m.,Eastern Time. The conference takes place ...
Cached Biology Technology:Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family 2Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family 3Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany 2ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference 2
...
... Apoptosis is an evolutionarily conserved form ... cellular process. The central component of ... enzymes called caspases. These enzymes participate ... triggered in response to pro-apoptotic signals and ...
... System provides optimized reagents and protocols for ... genes by insertion of group II introns. ... group II introns and utilizes a simple ... II intron for specific insertion into the ...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Biology Products: